Sacubitril/Valsartan and Dapagliflozin in Patients with a Failing Systemic Right Ventricle: Effects on the Arrhythmic Burden

2024

Effects of Sacubitril/Valsartan and Dapagliflozin on Arrhythmias in Patients with a Failing Systemic Right Ventricle

Sample size: 46 publication 10 minutes Evidence: moderate

Author Information

Author(s): Ciriello Giovanni Domenico, Altobelli Ippolita, Fusco Flavia, Colonna Diego, Correra Anna, Papaccioli Giovanni, Romeo Emanuele, Scognamiglio Giancarlo, Sarubbi Berardo, Nicolosi Gian Luigi

Primary Institution: Adult Congenital Heart Disease and Congenital and Familial Arrhythmias Unit, Monaldi Hospital, Naples, Italy

Hypothesis

Can guideline-directed medical therapy including sacubitril/valsartan and dapagliflozin reduce the arrhythmic burden in patients with a failing systemic right ventricle?

Conclusion

The study suggests that guideline-directed medical therapy with sacubitril/valsartan and dapagliflozin may reduce the incidence of arrhythmic events in patients with a failing systemic right ventricle.

Supporting Evidence

After a median follow-up of 36 months, arrhythmic events occurred in 28% of patients.
Survival analysis showed a significant reduction in clinically relevant arrhythmias at follow-up.
Patients with no arrhythmic events had lower NT-proBNP values at the last evaluation.

Takeaway

This study found that certain heart medications can help reduce dangerous heart rhythms in patients with a specific heart condition.

Methodology

The study retrospectively reviewed medical records of patients with a failing systemic right ventricle, analyzing arrhythmic events before and after starting guideline-directed medical therapy.